Neoadjuvant combination immunotherapy in MSI/dMMR colorectal cancer

被引：0

作者：

Suarez-Carmona, Meggy ^{[1
,2
]}

Halama, Niels ^{[1
,2
,3
,4
]}

机构：

[1] German Canc Res Ctr, Dept Canc Immunol & Canc Immunotherapy, Heidelberg, Germany

[2] Helmholtz Inst Translat Oncol HI TRON, Mainz, Germany

[3] Johannes Gutenberg Univ Mainz, Univ Canc Ctr Mainz UCT Mainz, Univ Med Ctr, Mainz, Germany

[4] Johannes Gutenberg Univ Mainz, Univ Med Ctr, Dept Hematol Med Oncol & Pneumol, Mainz, Germany

来源：

TRENDS IN CANCER | 2024年 / 10卷 / 12期

关键词：

MISMATCH REPAIR-DEFICIENT; NIVOLUMAB;

D O I：

10.1016/j.trecan.2024.10.006

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Neoadjuvant immune checkpoint inhibition (ICI) is a new approach to treat patients with colorectal cancer (CRC). The effects of combined neoadjuvant ICI in locally advanced, DNA mismatch repair (dMMR)-deficient/microsatellite instable (MSI) CRC were recently reported by de Gooyer et al. from the NICHE-3 trial. Further studies will determine whether these impressive pathological responses lead to long-term clinical benefit.

引用

页码：1093 / 1094

页数：2

共 50 条

[41] Neoadjuvant envafolimab in a patient with MSI-H/dMMR colon cancer: a case report and literature review
Chen, Ziwei
Zhou, Jingrui
Chen, Weimin
Wu, Tao
Lian, Ke
Shen, Tao
IMMUNOTHERAPY, 2024, 16 (10) : 649 - 657
[42] Unraveling Resistance to Immunotherapy in MSI-High Colorectal Cancer
Heregger, Ronald
Huemer, Florian
Steiner, Markus
Gonzalez-Martinez, Alejandra
Greil, Richard
Weiss, Lukas
CANCERS, 2023, 15 (20)
[43] Combination of AKT1 and CDH1 mutations predicts primary resistance to immunotherapy in dMMR/MSI-H gastrointestinal cancer
Wang, Zhenghang
Zhang, Qi
Qi, Changsong
Bai, Yuezong
Zhao, Feilong
Chen, Hui
Li, Zhongwu
Wang, Xicheng
Chen, Mifen
Gong, Jifang
Peng, Zhi
Zhang, Xiaotian
Cai, Jinping
Chen, Shiqing
Zhao, Xiaochen
Shen, Lin
Li, Jian
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (06)
[44] Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant
Yang, Chang
Xia, Bai-Rong
Zhang, Zhao-Cong
Zhang, Yong-Jian
Lou, Ge
Jin, Wei-Lin
FRONTIERS IN IMMUNOLOGY, 2020, 11
[45] Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours
Sidaway, Peter
NATURE REVIEWS CLINICAL ONCOLOGY, 2023, 20 (03) : 138 - 138
[46] Results of phase I-II bridging study for Nous-209, a neoantigen cancer immunotherapy, in combination with pembrolizumab as first line treatment in patients with advanced dMMR/MSI-h colorectal cancer
Overman, Michael J.
Maurel, Joan
Oberstein, Paul Eliezer
Rosello-Keranen, Susana
Le, Dung T.
Pedersen, Katrina Sophia
Mukherjee, Sarbajit
D'Alise, Anna Morena
Leoni, Guido
Siani, Loredana
Scarselli, Elisa
Faivre, Thea
Delaite, Patricia
Gogov, Sven
Fakih, Marwan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[47] Neoadjuvant pembrolizumab shows promise in MSI-H/dMMR solid tumours
Peter Sidaway
Nature Reviews Clinical Oncology, 2023, 20 : 138 - 138
[48] Evaluating the predictive value of endoscopic findings for residual colorectal cancer following neoadjuvant combination immunotherapy
Li, Yue-Gang
Han, Cheng-Cheng
Zhuang, Meng
Zhao, Wei
Hu, Gang
Qiu, Wen-Long
Wang, Xi-Shan
Tang, Jian-Qiang
WORLD JOURNAL OF GASTROINTESTINAL SURGERY, 2025, 17 (01):
[49] Early and easy-to-retrieve predictive biomarkers of resistance to immunotherapy in microsatellite instability (MSI)/mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC)
Vaghi, C.
Ros Montana, F. J.
Mambrilla, M.
Navarro Garces, V.
Comas, R.
Salva Ballabrera, F.
Baraibar Argota, I.
Saoudi Gonzalez, N.
Rodriguez Castells, M.
Garcia Rodriguez, A.
Alcaraz, A.
Tabernero, J.
Elez Fernandez, M. E.
ANNALS OF ONCOLOGY, 2024, 35 : S56 - S57
[50] COST-EFFECTIVENESS ANALYSIS OF PEMBROLIZUMAB FOR ADVANCED COLORECTAL CANCER WITH MSI-HIGH OR DMMR IN JAPAN
Taniguchi, S.
Moriwaki, K.
Morimoto, K.
Shimozuma, K.
VALUE IN HEALTH, 2024, 27 (06) : S150 - S151

← 1 2 3 4 5 →